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Concern persists about the potential negative inotropic
effects of calcium channel blockers in patients with se-
verely depressed myocardial function. Therefore, intra-
venous diltiazem (100 to 200 ltg/kg per min infusion)
was administered for 40 minutes followed by oral dil-
tiazem (90 to 120 mg/8 hours) for 24 hours to patients
with advanced congestive heart failure (New York Heart
Association class III to IV, mean ejection fraction 26 ±
4 [SD)). Intravenous diltiazem (eight patients) increased
cardiac index 20% (2.05 ± 0.8 to 2.47 ± 0.8 liters/min
per m2, p < 0.01), stroke volume index 50% (22 ± 9
to 33 ± 12 ml/m2, p < 0.001) and stroke work index
27% (19 ± 10 to 24 ± 10 g_m/m2, p < 0.05); while
reducing heart rate 23% (97 ± 18 to 75 ± 11 beats/min,
p < 0.01), mean arterial pressure 18% (95 ± 13 to 78
Appropriate concerns persist regarding the potential nega-
tive inotropic properties of the calcium channel blocking
drugs, particularly when used in patients with depressed left
ventricular performance. These structurally heterogeneous
compounds share three basic hemodynamic characteristics:
peripheral and coronary artery vasodilation, reflex sympa-
thetic stimulation and myocardial depression (I). The first
two properties tend to augment left ventricular performance
and mitigate or abrogate drug-induced negative inotropism
under usual circumstances (1,2). However, the net cardio-
circulatory response to such agents may differ depending
on the calcium channel blocking agent employed (3,4), the
dose, the use of concomitant cardioactive drugs (5,7) and
the hemodynamic status of the patient (8).
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± 7 mm Hg) and pulmonary wedge pressure 34% (29
± 9 to 19 ± 7 mm Hg), without altering maximal first
derivative of left ventricular pressure (dP/dtmax)' Oral
diltiazem (seven patients) produced equivalent hemo-
dynamic effects. Transient junctional arrhythmias were
observed in three of eight patients with intravenous dil-
tiazem and one of seven patients with oral diltiazem.
It is concluded that intravenous and short-term oral
diltiazem improve left ventricular performance and re-
duce myocardial oxygen demand by heart rate and af-
terload reduction without significantly depressing con-
tractile function in severe congestive heart failure. Caution
should be exercised to avoid potential adverse, drug-
induced electrophysiologic effects in such patients.
Several clinical investigations detailing the beneficial ef-
fects of nifedipine as vasodilator therapy for congestive heart
failure have been reported (8-11). However, problems re-
garding patient selection and the use of a single acute dose
of nifedipine preclude extrapolation of these data to subacute
or chronic administration of calcium blocking agents to pa-
tients with heart failure because of depressed myocardial
function. In addition, acute pulmonary edema and hypo-
tension with reduced cardiac output after parenteral and oral
verapamil and oral nifedipine have been reported (12-14).
By contrast, there have been no investigations detailing the
hemodynamic actions of diltiazem, the calcium blocking
agent with the least negative inotropic effects (1,15), in
patients with severe heart failure.
Previously we demonstrated (3) that diltiazem produced
the least myocardial depression of the available calcium
blockers when given in equimolar, equihypotensive doses
by either the intravenous or intracoronary route in the awake,
preinstrumented dog with normal cardiovascular function.
However, more recently we observed (16) that this drug
substantially reduced the rate of left ventricular pressure
development (dP/dtmax) in an animal model of high output
congestive heart failure with enhanced left ventricular func-
tion, when given in a dose which produced no negative
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inotropic effect in the same animal before the induction of
congestive heart failure. Accordingly, we designed the pres-
ent investigation to assess the effects of intravenous dilti-
azem on left ventricular performance and evaluate the hemo-
dynamic effects of high dose oral diltiazem in patients with
severe congestive heart failure due to myocardial depression.
Methods
Study patients. Patients referred for cardiac catheter-
ization for routine diagnostic purposes were invited to par-
ticipate in the study. Eight patients (five men and three
women), mean age 49 years (range 31 to 56), consented to
the experimental protocol, which was approved on April
21, 1981, by the Institutional Review Board of The Uni-
versity of Texas Health Science Center at San Antonio. All
patients had New York Heart Association functional class
III or IV heart failure, despite conventional medical treat-
ment which included digoxin and furosemide in all cases
and vasodilator therapy in five. All cardioactive medications
were withheld at least 24 bours before and for the entire
duration of the study. Additional criteria included the ab-
sence of acute myocardial infarction within 6 months or
valvular heart disease. Four of the subjects had ischemic
cardiomyopathy and four had idiopathic dilated cardio-
myopathy (Table I).
Cardiac catheterization procedure. Catheterization was
performed in the fasting state, without premedication, using
the brachial artery approach. All eight patients had systemic
arterial pressure monitored by a percutaneous cannula. Bal-
loon flow-directed catheters were employed to measure right
heart pressures, and cardiac output was recorded in triplicate
by computer-derived indicator-dilution technique (Lyons In-
struments). Both systemic arterial and right-sided pressures
were measured by fluid-filled catheter systems utilizing Sta-
tham P23Db strain gauges and recorded on an Electronics
for Medicine VRl6 recorder. Left-sided pressure and first
derivative of left ventricular pressure (dP/dt) were obtained
in six patients using an 8 French high fidelity micromano-
meter-tipped angiographic catheter. Electronic calibration.
differentiation and correction for zero drift were accom-
plished by methods previously reported for this laboratory
(17).
Simultaneous biplane left ventricular cineangiography
was performed in the 30° right anterior oblique and 60° left
anterior descendingl20 cranially angulated projections (CGR
Double Angiomax) after the injection of 40 and 70 ml,
respectively. of radiopaque contrast (Renografin-76) at 10
to 20 mils, at a frame rate of 60/s. Image analysis was
performed on one of the first three sinus beats after contrast
injection when the effects of contrast material on myocardial
performance are negligible. Left ventricular end-diastolic
and end-systolic volumes were calculated using a modified
biplane formula (18).
ExperimentaI protocol. Intravenous phase. The ex-
perimental protocol was divided into two phases: an intra-
venous phase in the catheterization laboratory and an oral
phase in the coronary care unit. All eight patients underwent
the intravenous phase. Control measurements (C 1) were re-
corded when systemic arterial and pulmonary wedge pres-
sures were unchanged for a minimum of 15 minutes. Dil-
tiazem (Marion Laboratories) was then administered in either
a 100 (four patients) or a 200 (four patients) ILg/kg intra-
venous bolus infusion (dissolved in normal saline solution),
with a drug infusion sufficient to produce a 15 to 20%
decrease in steady state mean systemic arterial pressure (mean
diltiazem dose 13 ± 2 ILg/kg per min). Steady state mea-
surements were made during 5, 10, 20 and 40 minutes of
drug administration. Diagnostic coronary arteriography and
biplane left ventriculography were performed 20 minutes
after cessation of the intravenous drug infusion when all
hemodynamic variables had returned to baseline.
Oral phase. Seven of these eight patients consented to
the oral phase of the study. This involved transfer to the
coronary care unit, intravenous saline solution administra-
tion and a mean delay of 2.5 hours postcatheterization for
the osmotic effects of iodinated contrast medium to dissipate
and hemodynamic profiles to return to prediltiazem baseline
Table 1. Characteristics of Patients With Severe Congestive Heart Failure Given Diltiazem
Age Functional LVEDVIt Ejection Fractiont
Patient (yr) Diagnosis Class* (cc/m2 ) (%)
1 56 PMD III 300 30
2 52 IHD IV IR9 30
3 53 PMD IV 19R:\: 15:\:
4 51 IHD IV IR4 26
5 31 PMD III 173 28
6 62 IHD III 142 32
7 37 PMD IV IRO II
8 53 IHD IV 204 25
Mean ± SD 49 ± 10 1lJ6 :+: 46 24 ± 6
*New York Heart Association criteria; tbiplane left ventriculography: tradionuclide ventriculography. IHD = ischemic cardiomyopathy; LVEDVI
= left ventricular end-diastolic volume index; PMD = primary myocardial disease.
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Results
Control hemodynamic data (Tables 1 and 2; Fig. 1 to
4). Control data (C,) for the group before intravenous dil-
tiazem included heart rate 97 ± 18 beats/min, mean arterial
pressure 95 ± 13 mm Hg, pulmonary capillary wedge pres-
sure 29 ± 9 mm Hg and cardiac index 2.05 ± 0.8 liters/min
per m2 . The left ventricular end-diastolic volume index was
196 ± 46 ml and the mean ejection fraction was 24 ± 6%.
Left ventricular volumes and ejection fraction were deter-
mined by biplane angiography in seven patients and by
radionuclide angiography in one patient. There were no
significant differences in control hemodynamic values be-
tween the intravenous and oral phases of the investigation.
Hemodynamic effects of diltiazem. Mean steady state
hemodynamic alterations produced at each time period by
intravenous and oral diltiazem appear in Table 2. Figures
2 through 4 compare changes in selected hemodynamic vari-
ables during 20 minutes and 24 hours of intravenous and
oral diltiazem, respectively.
Rate of pressure development (Fig. J). The effect of
intravenous diltiazem on the rate of pressure development
(dP/dtmax) in the left ventricle was evaluated in six patients.
In two patients, dP/dt was unobtainable because of complete
left bundle branch block (Case I) or inability to advance
levels. Control measurements (C2) were then performed when
systemic arterial and pulmonary wedge pressures were sta-
ble for a minimum of 30 minutes. Oral diltiazem was ad-
ministered to one patient in a dose of 90 mg every 8 hours,
and to six patients in a dose of 120 mg every 8 hours. Serial
measurements of hemodynamic variables were made for a
24 hour period. Plasma diltiazem levels were assessed con-
comitantly with hemodynamic measurements during intra-
venous and oral drug administration by high pressure liquid
chromatography.
Data analysis. Mean systemic and pulmonary artery
pressures were determined by electronic filtration. Derived
hemodynamic variables were determined as follows: CI =
CO/body surface area (liters/min per m2), PVR = 80 x
(MAP - PCWP)/CO (dynes's'cm- 5), SVI = CIIHR (mllbeat
per m2), SVR = 80 x MAP/CO (dynes's'cm- 5), and SWl
= SVI x (MAP - PCWP) x 0.0136 (g-m/m2), where
CI = cardiac index; CO = cardiac output; HR = heart
rate; PVR = pulmonary vascular resistance; SVI = stroke
volume index; SVR = systemic vascular resistance; and
SWI = stroke work index.
Statistical analyses. These were performed using a re-
peated measures one-way analysis of variance (Program
BMDP 2V) for intragroup interaction. Dunnet's t test was
then used to assess statistical significance among group mean
values. The level of significance was chosen as probability
[p] ::; 0.05. Results are expressed as the mean ± I standard
deviation (SD).
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Figure 2. Effects of intravenous and oral diltiazem on heart rate
at 20 minutes and 24 hours of drug administration, respectively.
A significant negative chronotropic effect was present after both
intravenous and oral diltiazem (T = SE).
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Figure 1. Effects of intravenous (Iv) diltiazem on maximal rate
of size of left ventricular pressure (dP/dtmax) in six patients. There
is no significant difference from control (C) at 5, 10 or 20 minutes
of drug infusion.
the high fidelity catheter into the left ventricle (Case 3).
There was no significant change in dP/dtmax from control
for the group during 5, 10 or 20 minutes of drug infusion
(for example, control = 1,165 ± 171 mm Hg/s versus 20
minute diltiazem infusion = 1,062 ± 191, P = NS). How-
ever, dP/dtmax was reduced in two of the six patients during
intravenous diltiazem administration.
Heart rate, aortic and arterial pressure. Heart rate de-
creased significantly during 20 minutes of intravenous dil-
tiazem from 97 ± 18 to 75 ± II beats/min (a decrease of
23%, p < 0.001) and from 88 ± 18 to 76 ± 10 beats/min
(a decrease of 13%, p < 0.01) during 24 hours of oral
diltiazem (Fig. 2). Mean aortic pressure also declined from
95 ± 13t078 ± 7mmHg(adecreaseofI8%,p<0.01),
although there was no significant change in arterial pressure
after the oral diltiazem (93 ± 18 versus 89 ± 16 mm Hg,
p = NS) at the same time intervals.
Pulmonary capillary wedge pressure. The changes from
control in mean pulmonary capillary wedge pressure produced
by intravenous oral diltiazem are recorded in Table 2. For
example, pulmonary wedge pressure was reduced from 29
± 9 to 21 ± 9 mm Hg (a decrease of 28%, p < 0.001)
during 20 minutes of intravenous diltiazem administration,
but was not significantly altered during 24 hours of oral
administration (25 ± 7 to 22 ± 6 mm Hg, p = NS).
Cardiac index and stroke volume index (Table 2. Fig.
3). The cardiac index increased from 2.05 ± 0.8 to 2.47
± 0.8 liters/min per m2 (+ 21%, P < 0.01) during intra-
venous diltiazem, and from 1.89 ± 0.6 to 2.67 ± 0.6
liters/min per m2 (+ 46%, P < 0.01) during oral diltiazem.
The stroke volume index increased from 22 ± 9 to 33 ±
12 ml/m2 (+ 55%, P < 0.001) after intravenous diltiazem,
50P~OI
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and from 23 ± 9 to 35 ± 8 mllm2 (+ 57%, P < 0.001)
with oral drug administration. Because heart rate declined
significantly after both intravenous and oral administration,
the observed increases in cardiac index are entirely a func-
tion of the substantial drug-induced augmentation of stroke
volume. The observed alteration in stroke volume index,
plus arterial and pulmonary capillary wedge pressure, re-
sulted in significant increases in stroke work index during
both intravenous (19 ± 10 to 24 ± 10 g-m/m2 , p < 0.05)
and oral (20 ± 10 to 33 ± 12 g-m/m2, p < 0.05) diltiazem
(Table 2) at 20 minutes and 24 hours of drug administration,
respectively.
Systemic and pulmonary vascular resistances (Table 2,
Fig. 4). Systemic vascular resistance declined by 34% from
2,465 ± 410 to 1,637 ± 460 dynes's'cm- s (p < 0.001)
during 20 minutes of intravenous diltiazem, while 24 hours
of oral diltiazem administration reduced systemic resistance
by 27% from 2,466 ± 437 to 1,794 ± 271 (p < 0.01).
Pulmonary vascular resistance declined similarly by 43%
during intravenous diltiazem (382 ± 144 to 216 ± 89
dynes's'cm- s, p < 0.01) and 39% (435 ± 143 to 278 ±
81 dynes's'cm- s, p :s:; 0.05) during oral drug administration.
Plasma diltiazem levels (Table 2). The mean plasma dil-
tiazem level that occurred after 20 minutes of intravenous
diltiazem infusion was 430 ± 103 ng/ml (range ISO to 846).
A mean plasma concentration of 307 ± 72 ng/ml (range
66 to 650) was measured after 24 hours of oral drug admin-
istration. These levels are considerably above the 50 to ISO
ng/ml range, which has previously been shown to be clin-
Figure 4. Effects of intravenous and oral diltiazem on systemic
(left) and pulmonary (right) vascular resistance. Significant re-
ductions in both variables were observed with both forms of admin-
istration (T = SE).
ically effective in the management of stable angina pectoris
and coronary arterial spasm (19).
Adverse effects. During the intravenous phase of dil-
tiazem administration three of four patients who were given
the 200 j.Lg bolus infusion developed a transient junctional
rhythm. One of these three patients developed relative hy-
potension consequent to the bradyarrhythmia and was with-
drawn from further study. No patient had any arrhythmia
after the 100 j.Lg/kg bolus. One of the seven patients re-
ceiving 360 mg/day of oral diltiazem had an intermittent,
hemodynamically insignificant junctional rhythm which oc-
curred during oral diltiazem administration and abated after
drug withdrawal.
Discussion
Hemodynamic effects of diltiazem in congestive heart
failure. The results of this investigation suggest that steady
state intravenous and short-term oral diltiazem administra-
tion produced substantial improvement in left ventricular
performance in a group of patients with severe congestive
heart failure because of ischemic heart disease or cardio-
myopathy. Beneficial hemodynamic effects included sig-
nificant augmentation of cardiac stroke volume and stroke
work indexes accompanied by decreases in heart rate and
systemic and pulmonary vascular resistances during both
intravenous and oral drug administration. Preload, as as-
sessed by pulmonary capillary wedge pressure, was signif-
icantly reduced during the intravenous but not during the
oral phase of the study. The reduction in left ventricular
filling pressure occurred despite the decrease in heart rate
with consequent increase in diastolic filling period. Al-
though previous studies (1, 16) failed to demonstrate direct
effects of calcium channel inhibition on venous smooth mus-
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cle, reflex increases in venous capacitance or the large in-
creases in stroke volume caused by drug induced afterload
reduction may have decreased the pulmonary wedge pres-
sure. Because left ventricular volumes were not measured
after diltiazem, we cannot exclude an increase in diastolic
chamber compliance as an alternative explanation for the
observed reduction in left-sided filling pressures. Myo-
cardial contractile state as assessed by left ventricular dP/dtmax
was not significantly diminished for the group by the dose
of diltiazem employed in this investigation. However, the
sample size was small (six patients) and calcium blockade-
induced reductions in dP/dt were observed in two patients
(Fig. I).
The mechanism responsible for the observed hemody-
namic effects is undoubtedly diltiazem-induced afterload re-
duction, produced by systemic arteriolar vasodilation. Al-
ternatively, coronary arterial vasodilation produced by
diltiazem may have enhanced left ventricular systolic per-
formance. This possibility seems less likely because no pa-
tient had clinical or electrocardiographic evidence of isch-
emia during the study and no difference was observed in
the magnitude or direction of hemodynamic response be-
tween those patients with ischemic or idiopathic
cardiomyopathy.
Chronotropic effects of diltiazem in congestive fail-
ure. We observed significant decreases in heart rate in these
patients after intravenous (23% decrease) and oral (13%
decrease) administration of diltiazem. Each of the calcium
antagonists has been shown to directly reduce the frequency
of sinoatrial depolarization after injection of the agents into
the sinoatrial nodal artery (20,21). However, during sys-
temic administration this direct negative chronotropic effect
is usually partially or completely offset by baroreceptor-
mediated reflex increases in beta-adrenergic tone in response
to the systemic vasodilation produced by these drugs (3,4).
The negative chronotropic response produced by diltiazem
in this study may be due to the blunted baroreceptor func-
tion, coupled with the high resting level of sympathetic tone
observed in chronic congestive heart failure, which ampli-
fied the direct effect of this drug on sinus node function.
The transient junctional rhythm disturbances noted in some
of our patients may have been an extension of these elec-
trophysiologic properties. Alternatively, the direct effect of
calcium entry blockade on the proximal conduction system
may have been augmented by the elevated plasma diltiazem
levels achieved in these patients (Table 2). These levels are
clearly in excess of those reported after similar dosages of
oral diltiazem in human beings without heart failure (19).
Further investigation is indicated to determine the reason(s)
for the apparent altered drug pharmacokinetics of this agent
in patients with circulatory congestion.
Comparison with nijedipine. The salutory effects of dil-
tiazem on left ventricular performance in severe congestive
heart failure observed in this investigation are similar to
those previously reported after acute single dose oral admin-
istration of nifedipine in patients with variably diminished
cardiac function of multiple causes (8-11). In contrast, Mat-
sui et al. (22) were unable to demonstrate sustained hemo-
dynamic improvement after 24 hours of oral nifedipine given
at 4 hour intervals in patients with depressed left ventricular
performance, although afterload reduction with increased
cardiac output was noted after the initial dose. Nifedipine
administration was associated with either no change or mod-
est increases in heart rate in each of the aforementioned
studies, in contrast to the significant decrease in heart rate
observed after acute intravenous and short-term oral dilti-
azem in our investigation. These data suggest that, at least
acutely, administration of nifedipine can produce beneficial
hemodynamic effects by afterload reduction and reflex beta-
adrenergic stimulation, even in patients with clinically ad-
vanced congestive heart failure. Whether these effects are
sustained after subacute or short-term drug therapy is un-
certain and reports of cardiac failure associated with nife-
dipine, and with (5,13) and without (14) concomitant beta-
adrenergic blockade have appeared.
Comparison with verapamil. Verapamil in clinically rel-
evant doses has been shown to impair left ventricular per-
formance in conscious dogs with normal cardiac function
(3,4,23). The negative inotropic properties of this agent are
augmented in the conscious animal (23) and in human beings
(6,7), when sympathetic reflexes are blocked by prior beta-
adrenergic blockade. By contrast, equihypotensive, equi-
molar doses of diltiazem produced no decrease in left ven-
tricular function before or after beta-adrenergic blockade
(3,4). Short-term studies dealing with the effects of vera-
pamil in patients with normal or mildly reduced left ven-
tricular function have demonstrated peripheral systemic va-
sodilation associated with modest improvement of systolic
function (24); however, both Singh and Roche (25) and
Lewis et al. (26) observed decreases in dP/dt associated
with increases in left ventricular diastolic pressure after in-
travenous verapamil. More recently, Chew et al. (12) re-
ported reductions in mean arterial pressure accompanied by
a decrease in stroke volume index and an abrupt increase
in mean pulmonary wedge pressure associated with clinical
evidence of heart failure in three patients with severely
reduced basal ejection fraction and mean pulmonary cap-
illary wedge pressure greater than 20 mm Hg. These data
suggest that in contrast to our findings with diltiazem, ver-
apamil may cause frank deterioration of left ventricular per-
formance in patients with severe congestive heart failure.
Conclusions. Intravenous and short-term oral diltiazem
in maximally recommended therapeutic doses produces sus-
tained improvement in global left ventricular performance
in patients with severe cardiomyopathic congestive heart
failure. The determinants of myocardial oxygen demand
were favorably influenced in the absence of any significant,
drug-induced negative inotropic effects. It should be em-
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phasized that the favorable hemodynamic actions observed
in our small patient group do not preclude the possibility
of adverse hemodynamic or electrophysiologic effects in an
individual patient. Until more experience is gained, all cal-
cium blocking agents should be used with caution in patients
with left ventricular dysfunction. Clearly, additional studies
are needed to demonstrate potential long-term hemodynamic
benefits and further delineate the pharmacokinetics of these
agents in congestive heart failure.
We acknowledge Marion Laboratories, Kansas City, Missouri, for sup-
plying diltiazem and measuring diltiazem blood levels. We also appreciate
the secretarial assistance of Louise Williams.
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